Please login to the form below

Not currently logged in
Email:
Password:

Akari Therapeutics strengthens board

Hires Michael Grissinger and Dr Peter Feldschreiber

Mike GrissingerBiopharmaceutical company Akari Therapeutics has bolstered its board of directors with the addition of Michael Grissinger and Dr Peter Feldschreiber.

Grissinger (pictured right) has spent 22 years at Johnson & Johnson, holding positions of vice president and head of worldwide pharmaceutical licencing, as well as vice president and head of worldwide pharmaceutical corporate development and M&A.

His expertise has seen him led transactions across a broad span of deal-types, geographies, and therapeutic disease areas and he brings experience in business and corporate development, finance, marketing and strategic planning to Akari.

Alongside Grissinger, Dr Peter Feldschreiber also joins the board bringing 20 years’ experience in the pharmaceutical industry.

He has held appointments as senior medical assessor and special litigation coordinator to the healthcare products regulatory agency.

Ray Prudo, executive chairman of Akari Therapeutics, said: “We are pleased to strengthen our board with two individuals that bring such a range and depth of healthcare industry experience.

“As Akari continues its mission to develop and commercialise treatments for orphan autoimmune and inflammatory disease, we look forward to benefitting from Michael’s expertise as a successful business and corporate development leader and Peter’s insight as a medical doctor with experience both in the pharmaceutical industry and the legal and regulatory aspects of healthcare.”

31st January 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics